The sixth season promises an epic rebellion inside the dystopian authoritarian “hellscape”, and an ending that will leave a ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Multi-Factor Investor model based on the published ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Who are the true pioneers of quantitative finance? Even for us here at FT Alphaville, it’s a difficult ...

Looking for the MTG Commander banlist? With such a vast format, knowing which cards you aren’t allowed to use can be tricky. In this guide you’ll find a list of every card that’s forbidden in ...

Gilead said two ex­per­i­men­tal once-a-year ver­sions of its HIV pre­ven­tion shot lenaca­pavir passed muster in an ear­ly-stage study with a small group of healthy par­tic­i­pants … ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

Well-known to followers of the blogosphere and seekers of intelligent, percipient commentary on public policy, Kevin Drum passed away Friday after a long battle with multiple myeloma, a cancer of ...

Gilead Sciences (GILD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the ...

Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a cluster ...